Strategic Asset Divestment Ayala Pharmaceuticals recently sold its main assets, the AL101 and AL102 programs, to Immunome for an initial $20 million and potential milestone payments, indicating a focus shift and open opportunities for licensing, partnerships, or acquiring new innovative assets.

Pipeline Progress & Collaborations With lead candidates like AL102 for desmoid tumors and collaborations with Novartis for multiple myeloma, Ayala demonstrates a robust oncology pipeline that may interest sales partners seeking early- to mid-phase therapeutics or co-development opportunities.

Recent Company Expansion The merger with Biosight enhances Ayala’s portfolio and geographic reach, creating new avenues for market entry and partnerships across different regions and cancer types.

Funding & Market Potential With a current funding of $25 million and revenues between $1 million and $10 million, Ayala presents a growing but still emerging market player open to strategic partnerships to accelerate clinical development and commercialization.

Regulatory & Clinical Milestones Having completed a successful End-of-Phase 2 meeting with the FDA for AL102, Ayala is well-positioned to advance its clinical programs, offering opportunities for sales and distribution partners aligned with upcoming regulatory approvals.